Payment overview · 2025
General Payments
$553.94
30 reported records · 13 companies
Healthcare provider profile · identity verified
Jennifer Feldbauer, CRNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · DU BOIS, PA · NPI 1063828952
Verified facts
What the public records show
CMS Open Payments records show Jennifer Feldbauer, CRNP received $553.94 in general payments during 2025 across 30 reported records.
Amgen Inc. accounted for 24.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 236 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $133.66 | 24.1% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $102.67 | 18.5% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $69.12 | 12.5% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $38.79 | 7.0% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $34.99 | 6.3% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $34.68 | 6.3% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $30.29 | 5.5% | 1 | 2025 |
| Sonex Health, Inc. | Unresolved — no canonical attribution shown | $25.77 | 4.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.76 | 3.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.86 | 3.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.67 | 2.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.50 | 2.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.18 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $553.94 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $114.66 | 6 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $69.12 | 4 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $48.75 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $48.10 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $38.79 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $37.33 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $34.99 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $34.68 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $33.53 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $30.29 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $30.29 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $30.29 | 1 | 2025 |
Source payment records
|
|||||
| SX-ONE MICROKNIFE Normalized: sx one microknife |
Device | Sonex Health, Inc. | $25.77 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.76 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.24 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.50 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
51 | 16 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
236 | 52 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
82 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 589 | 167 |
| Levothyroxine Sodium | Levothyroxine Sodium | 439 | 118 |
| Lisinopril | Lisinopril | 437 | 119 |
| Amlodipine Besylate | Amlodipine Besylate | 329 | 91 |
| Omeprazole | Omeprazole | 322 | 86 |
| Metformin Hcl | Metformin Hcl | 241 | 61 |
| Eliquis | Apixaban | 236 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 194 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 185 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 184 | 57 |
| Metoprolol Tartrate | Metoprolol Tartrate | 164 | 44 |
| Valsartan | Valsartan | 164 | 44 |
| Citalopram Hbr | Citalopram Hydrobromide | 161 | 40 |
| Sertraline Hcl | Sertraline Hcl | 157 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 147 | 40 |
| Famotidine | Famotidine | 136 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 126 | 41 |
| Potassium Chloride | Potassium Chloride | 120 | 39 |
| Gabapentin | Gabapentin | 116 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 108 | 28 |
| Losartan Potassium | Losartan Potassium | 107 | 30 |
| Simvastatin | Simvastatin | 106 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 102 | 29 |
| Allopurinol | Allopurinol | 94 | 29 |
| Furosemide | Furosemide | 94 | 40 |
| Cephalexin | Cephalexin | 92 | 59 |
| Trazodone Hcl | Trazodone Hcl | 92 | 22 |
| Warfarin Sodium | Warfarin Sodium | 89 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 87 | 23 |
| Trulicity | Dulaglutide | 83 | 14 |
| Carvedilol | Carvedilol | 82 | 25 |
| Dutasteride | Dutasteride | 82 | 22 |
| Ozempic | Semaglutide | 82 | 19 |
| Tramadol Hcl | Tramadol Hcl | 80 | 17 |
| Memantine Hcl | Memantine Hcl | 79 | 21 |
| Donepezil Hcl | Donepezil Hcl | 78 | 21 |
| Finasteride | Finasteride | 75 | 22 |
| Montelukast Sodium | Montelukast Sodium | 74 | 21 |
| Methylprednisolone | Methylprednisolone | 70 | 61 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 68 | 16 |
| Januvia | Sitagliptin Phosphate | 67 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 66 | 15 |
| Xarelto | Rivaroxaban | 65 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 56 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 23 |
| Entresto | Sacubitril/Valsartan | 55 | 14 |
| Jardiance | Empagliflozin | 55 | 17 |
| Myrbetriq | Mirabegron | 51 | suppressed |
| Prednisone | Prednisone | 51 | 44 |
| Synthroid | Levothyroxine Sodium | 51 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | 15 |
| Lorazepam | Lorazepam | 48 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 42 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | suppressed |
| Atenolol | Atenolol | 41 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 31 |
| Fenofibrate | Fenofibrate Nanocrystallized | 38 | suppressed |
| Mirtazapine | Mirtazapine | 38 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 37 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 35 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Glimepiride | Glimepiride | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 28 |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Torsemide | Torsemide | 28 | suppressed |
| Azithromycin | Azithromycin | 26 | 23 |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Repatha Sureclick | Evolocumab | 26 | suppressed |
| Alprazolam | Alprazolam | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 18 |
| Nystatin | Nystatin | 25 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Meloxicam | Meloxicam | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | 15 |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Fentanyl | Fentanyl | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 16 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $553.94 · 30 records | Amgen Inc. | AIRSUPRA, BREZTRI, CAMZYOS, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, PROLIA, REPATHA, REXULTI, SX-ONE MICROKNIFE, UBRELVY, VAXNEUVANCE, Veozah, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error